Diagnosis and Treatment of Plasmodium vivax Malaria

Advances in Parasitology

Volumn 80, Issue , 2012, Pages 203-270

  Baird, Kevin J ^a   Maguire, Jason D ^b   Price, Ric N ^c  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

Anti relapse; Chemotherapy; Chloroquine; Diagnosis; Drug resistance; History; Plasmodium vivax; Primaquine

Indexed keywords

4 METHYLPRIMAQUINE; 8 AMINOQUINOLINE DERIVATIVE; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; HALOFANTRINE; ISOPENTAQUINE; LINCOSAMIDE DERIVATIVE; MEFLOQUINE; MEPACRINE; METHYLENE BLUE; MIRINAMYCIN; PAMAQUINE; PAMAQUINE PLUS QUININE SULFATE; PENTAQUINE; PIPERAQUINE; PRIMAQUINE; PRIMAQUINE DERIVATIVE; PYRONARIDINE; QUININE; QUININE SULFATE; QUINOCIDE; SONTOQUINE; TAFENOQUINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANRIGEN CAPTURE RAPID DIAGNOSTIC TEST; ARTICLE; BLACK URINE; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; CYANOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE TRANSMISSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; ENDEMIC DISEASE; EX VIVO STUDY; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYSIS; HISTORY OF MEDICINE; HUMAN; IN VIVO STUDY; JAUNDICE; LIFE CYCLE STAGE; LOW DRUG DOSE; MALARIA FALCIPARUM; MEROZOITE; MICROSCOPY; MOLECULAR DIAGNOSIS; MONOTHERAPY; MUSCLE CRAMP; NONHUMAN; PARASITE LOAD; PARASITEMIA; PATIENT COMPLIANCE; PLASMODIUM CYNOMOLGI; PLASMODIUM VIVAX MALARIA; POLYMERASE CHAIN REACTION; PRIMARY PREVENTION; PRIMATE; PRIORITY JOURNAL; RELAPSE; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISCOLORATION; STOMACH DISCOMFORT; STOMACH UPSET; TREATMENT PLANNING; URINE COLOR;

EID: 84870321438     PISSN: 0065308X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-397900-1.00004-9     Document Type: Chapter

References (242)

1. Agarwal R., Nath A., Gupta D. Noninvasive ventilation in Plasmodium vivax related ALI/ARDS. Intern. Med. 2007, 46:2007-2011.
2. Alving A.S., Craige B., Pullman T.N., Whorton C.M., Jones R.J., et al. Procedures used at Stateville penitentiary for the testing of potential antimalarial agents. J. Clin. Invest. 1948, 27:2-5.
3. Alving A.S., Eichelberger L., Arnold J., Edgcomb J. The clinical testing of antimalarial drugs at Stateville Penitentiary: semi annual report 1948-49. NIH Malaria Report No 87 USPHS Antimalarial Grant No 198 1949.
4. Alving A.S., Arnold J., Hockwald R.S., Clayman C.B., Dern R.J., et al. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J. Lab. Clin. Med. 1955, 46:301-306.
5. Alving A.S., Rucker K., Flanagan C.L., et al. Observations of primaquine in the prophylaxis and cure of vivax malaria. Proceedings of the 6th International Congress on Tropical Medicine and Malaria 7 1959, 203-209.
6. Alving A.S., Johnson C.F., Tarlov A.R., Brewer G.J., Kellermeyer R.W., et al. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration: a preliminary report. Bull. World Health Organ. 1960, 22:621-631.
7. Arinaitwe E., Sandison T.G., Wanzira H., Kakuru A., Homsy J., et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin. Infect. Dis. 2009, 49:1629-1637.
8. Arnold J., Alving A.S., Hockwald R.S., Clayman C.B., Dern R.J., et al. The effect of continuous and intermittent primaquine therapy on the relapse rate of Chesson strain vivax malaria. J. Lab. Clin. Med. 1954, 44:429-438.
9. Arnold J., Alving A.S., Hockwald R.S., Clayman C.B., Dern R.J., et al. The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria (Panama, P-F-6 strain). J. Lab. Clin. Med. 1955, 46:391-397.
10. Awab G.R., Pukrittayakamee S., Imwong M., Dondorp A.M., Woodrow C.J., et al. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malar. J. 2010, 9:105.
11. Bacon D.J., Jambou R., Fandeur T., Le Bras J., Wongsrichanalai C., et al. World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility. J. Infect. Dis. 2007, 6:120.
12. Baird J.K., Hoffman S.L. Primaquine therapy for malaria. Clin. Infect. Dis. 2004, 39:1336-1345.
13. Baird J.K., Surjadjaja C. Consideration of ethics in primaquine therapy against malaria transmission. Trends Parasitol. 2011, 27:11-16.
14. Baird J.K., Decker-Jackson J.E., Davidson D.E.J. An in vitro micro-volume procedure for rapid measurement of erythrocytic hexose monophosphate shunt activity. Int. J. Biochem. 1984, 16:1049-1052.
15. Baird J.K., Davidson D.E.J., Decker-Jackson J.E. Oxidative activity of hydroxylated primaquine analogs. Non-toxicity to glucose-6-phosphate dehydrogenase-deficient human red blood cells in vitro. Biochem. Pharmacol. 1986, 35:1091-1098.
16. Baird J.K., McCormick G.J., Canfield C.J. Effects of nine synthetic putative metabolites of primaquine on activity of the hexose monophosphate shunt in intact human red blood cells in vitro. Biochem. Pharmacol. 1986, 35:1099-1106.
17. Baird J.K., Basri H., Bangs M.J., Subianto B., Patchen L.C., et al. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am. J. Trop. Med. Hyg. 1991, 44:547-552.
18. Baird J.K., Basri H., Subianto B., Fryauff D.J., McElroy P.D., et al. Treatment of chloroquine resistance Plasmodium vivax with chloroquine and primaquine or halofantrine. J. Infect. Dis. 1995, 171:1678-1682.
19. Baird J.K., Fryauff D.J., Basri H., Bangs M.J., Subianto B., et al. Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am. J. Trop. Med. Hyg. 1995, 52:479-484.
20. Baird J.K., Leksana B., Masbar S., Fryauff D.J., Sutanihardja M.A., et al. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am. J. Trop. Med. Hyg. 1997, 56:621-626.
21. Baird J.K., Lacy M.D., Basri H., Barcus M.J., Maguire J.D., et al. Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin. Infect. Dis. 2001, 33:1990-1997.
22. Baird J.K., Fryauff D.J., Hoffman S.L. Primaquine for prevention of malaria in travelers. Clin. Infect. Dis. 2003, 37:1659-1667.
23. Baird J.K. Methylene blue-mediated hexose monophosphate shunt stimulation in human red blood cells in vitro: independence from intracellular oxidative injury. Int. J. Biochem. 1984, 16:1053-1058.
24. Baird J.K. Chloroquine resistance in Plasmodium vivax. Antimicrob. Agents Chemother. 2004, 48:4075-4083.
25. Baird J.K. Neglect of Plasmodium vivax malaria. Trends Parasitol. 2007, 23:533-539.
26. Baird J.K. Real-world therapies and the problem of vivax malaria. N. Engl. J. Med. 2008, 359:2601-2603.
27. Baird J.K. Resistance to therapies for infection by Plasmodium vivax. Clin. Microbiol. Rev. 2009, 22:508-534.
28. Baird J.K. Eliminating malaria - all of them. Lancet 2010, 376:1883-1885.
29. Baird J.K. Resistance to chloroquine unhinges vivax malaria therapeutics. Antimicrob. Agents Chemother. 2011, 55:1827-1830.
30. Baird J.K. Elimination therapies for the endemic malarias. Curr. Infect. Dis. Rep. 2012, 10.1007/s11908-012-0250-z.
31. Baird J.K. Tropical health sustainability. Encyclopedia of Sustainability Science and Technology 2012, 11134-11163. Springer Verlag, New York. R.A. Meyers (Ed.).
32. Barcus M.J., Basri H., Picarima H., Manyakori C., Sekartuti, et al. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Am. J. Trop. Med. Hyg. 2007, 77:984-991.
33. Barnadas C., Ratsimbasoa A., Tichit M., Bouchier C., Jahevitra M., et al. Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes. Antimicrob. Agents Chemother. 2008, 52:4233-4240.
34. Berliner R.W., Earle D.P., Taggart J.V., Zubrod C.G., Welch W.J., et al. Studies on the chemotherapy of the human malarias. VI. The physiological disposition, antimalarial activity, and toxicity of several derivatives of 4-aminoquinoline. J. Clin. Invest. 1948, 27:98-107.
35. Berliner R.W., Earle D.P.J., Taggart J.V., Atchley A., Shannon J.A. Studies on the chemotherapy of the human malarias. VII. The antimalarial activity of pamaquine. J. Clin. Invest. 1948, 27:108-113.
36. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blood 2008, 111:16-24.
37. Brosius O.T. Plasmochin in malaria. Section II p. 26-81 1927, Medical Department, Sixteenth Annual Report United Fruit Company, Boston.
38. Carlini M.E., White A.C., Atmar R.L. Vivax malaria complicated by adult respiratory distress syndrome. Clin. Infect. Dis. 1999, 28:1182-1183.
39. Carmona-Fonseca J., Maestre A. Prevention of Plasmodium vivax malaria recurrence: efficacy of the standard total dose of primaquine administered over 3 days. Acta Trop. 2009, 112:188-192.
40. Cedillos R.A., Warren M., Jeffery G.M. Field evaluation of primaquine in the control of Plasmodium vivax. Am. J. Trop. Med. Hyg. 1978, 27:466-472.
41. Chandramohan D., Jaffar S., Greenwood B. Use of clinical algorithms for diagnosing malaria. Trop. Med. Int. Health 2002, 7:45-52.
42. Chattopadhyay R., Velmurugan S., Chakiath C., Andrews Donkor L., Milhous W., et al. Establishment of an in vitro assay for assessing the effects of drugs on the liver stages of Plasmodium vivax malaria. PLoS ONE 2010, 5:e14275.
43. Chen N., Auliff A., Rieckmann K., Gatton M., Cheng Q. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J. Infect. Dis. 2007, 195:934-941.
44. Chen J.H., Lu F., Lim C.S., Kim J.Y., Ahn H.J., et al. Detection of Plasmodium vivax infection in the Republic of Korea by loop-mediated isothermal amplification (LAMP). Acta Trop. 2010, 113:61-65.
45. Chotivanich K., Udomsangpetch R., Chierakul W., Newton P.N., Ruangveerayuth R., et al. In vitro efficacy of antimalarial drugs against Plasmodium vivax on the western border of Thailand. Am. J. Trop. Med. Hyg. 2004, 70:395-397.
46. Chotivanich K., Sattabongkot J., Choi Y.K., Park J.S., Sritabal J., et al. Antimalarial drug susceptibility of Plasmodium vivax in the Republic of Korea. Am. J. Trop. Med. Hyg. 2009, 80:902-904.
47. Clark W.M. History of the co-operative wartime program. A Survey of Antimalarial Drugs 1941-1945 1946, vol. I:2-57. JW Edwards, Ann Harbor, Michigan.
48. Clayman C.B., Arnold J., Hockwald R.S., Yount E.H.J., Edgcomb J.H., et al. Toxicity of primaquine in Caucasians. J. Am. Med. Assoc. 1952, 149:1563-1568.
49. Clyde D.F., McCarthy V.C. Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. Am. J. Trop. Med. Hyg. 1977, 26:562-563.
50. Clyde D.F. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull. World Health Organ. 1981, 59:391-395.
51. Coatney G.R., Cooper W.C., Ruhe D.S. Studies in human malaria. VI. The organization of a program for testing potential antimalarial drugs in prisoner volunteers. Am. J. Epidemiol. 1948, 47:112-119.
52. Coatney G.R. Pitfalls in a discovery: the chronicle of chloroquine. Am. J. Trop. Med. Hyg. 1963, 12:121-128.
53. Coatney G.R. Primate Malarias 1971, US Government Printing Office, Washington, DC.
54. Collins W.E., Schwartz I.K., Skinner J.C., Morris C., Filipski V.K. The susceptibility of the Indonesian I/CDC strain of Plasmodium vivax to chloroquine. J. Parasitol. 1992, 78:344-349.
55. Collins W.E., Richardson B.B., Morris C.L., Sullivan J.S., Galland G.G. Salvador II strain of Plasmodium vivax in Aotus monkeys and mosquitoes for transmission-blocking vaccine trials. Am. J. Trop. Med. Hyg. 1998, 59:29-34.
56. Collins W.E., Sullivan J.S., Fryauff D.J., Kendall J., Jennings V., et al. Adaptation of a chloroquine-resistant strain of Plasmodium vivax from Indonesia to New World monkeys. Am. J. Trop. Med. Hyg. 2000, 62:491-495.
57. Collins W.E., Sullivan J.S., Galland G.G., Williams A., Nace D., et al. Observations on the Vietnam Palo Alto strain of Plasmodium vivax in two species of Aotus monkeys. J. Parasitol. 2005, 91:461-463.
58. Comfort N. The prisoner as model organism: malaria research at Stateville Penitentiary. Stud. Hist. Philos. Biol. Biomed. Sci. 2009, 40:190-203.
59. Congpuong K., Na-Bangchang K., Thimasarn K., Tasanor U., Wernsdorfer W.H. Sensitivity of Plasmodium vivax to chloroquine in Sa Kaeo Province, Thailand. Acta Trop. 2002, 83:117-121.
60. Cooper W.C., Myatt A.V., Hernandez T., Jeffery G.M., Coatney G.R. Studies in human malaria. XXXI. Comparison of primaquine, isopentaquine, SN-3883, and pamaquine as curative agents against Chesson strain vivax malaria. Am. J. Trop. Med. Hyg. 1953, 2:949-957.
61. Cooper R.D., Milhous W.K., Rieckmann K.H. The efficacy of WR238605 against the blood stages of a chloroquine resistant strain of Plasmodium vivax. Trans. R. Soc. Trop. Med. Hyg. 1994, 88:691-692.
62. Craige B., Alving A.S., et al. The Chesson strain of Plasmodium vivax malaria; relationship between prepatent period, latent period and relapse rate. J. Infect. Dis. 1947, 80:228-236.
63. Craige B.J., Jones R.J., Whorton C.M., Pullman T.N., Alving A.S., et al. Clinical standardization of pamaquine (plasmochin) in mosquito-induced vivax malaria, Chesson strain. Am. J. Trop. Med. Hyg. 1947, 27:309-315.
64. Curlin M.E., Barat L.M., Walsh D.K., Granger D.L. Noncardiogenic pulmonary edema during vivax malaria. Clin. Infect. Dis. 1999, 28:1166-1167.
65. Darlow B., Vrbova H., Gibney S., Jolley D., Stace J., et al. Sulfadoxine-pyrimethamine for the treatment of acute malaria in children of Papua New Guinea. II. Plasmodium vivax. Am. J. Trop. Med. Hyg. 1982, 31:10-13.
66. Davidson D.E., Ager A.L., Brown J.L., Chapple F.E., Whitmire R.E., et al. New tissue schizontocidal antimalarial drugs. Bull. World Health Organ. 1981, 59:463-479.
67. de Santana Filho F.S., Arcanjo A.R., Chehuan Y.M., Costa M.R., Martinez-Espinosa F.E., et al. Chloroquine-resistant Plasmodium vivax, Brazilian Amazon. Emerg. Infect. Dis. 2007, 13:1125-1126.
68. Di Lorenzo A., Marx R.L., Alving A.S., Jones R. Korean vivax malaria. IV. Curative effect of 15 milligrams of primaquine daily for 7 days. Am. J. Trop. Med. Hyg. 1953, 2:983-984.
69. Douglas N.M., Anstey N.M., Angus B.J., Nosten F., Price R.N. Artemisinin combination therapy for vivax malaria. Lancet Infect. Dis. 2010, 10:405-416.
70. Douglas N.M., Nosten F., Ashley E.A., Phaiphun L., van Vugt M., et al. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin. Infect. Dis. 2011, 52:612-620.
71. Dow G.S., Gettayacamin M., Hansukjariya P., Imerbsin R., Komcharoen S., et al. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). Malar. J. 2011, 10:212.
72. Downs W.G., Harper P.A., Lisansky E.T. Malaria and other insect-borne diseases in the South Pacific campaign. II. Epidemiology of insect borne diseases in Army troops. Am. J. Trop. Med. Hyg. 1947, 27:69-89.
73. Druilhe P., Brasseur P., Blanc C., Makler M. Improved assessment of Plasmodium vivax response to antimalarial drugs by a colorimetric double-site plasmodium lactate dehydrogenase antigen capture enzyme-linked immunosorbent assay. Antimicrob. Agents Chemother. 2007, 51:2112-2116.
74. Ehrman F.C., Ellis J.M., Young M.D. Plasmodium vivax Chesson Strain. Science 1945, 101:377.
75. Elliott J.H., O'Brien D., Leder K., Kitchener S., Schwartz E., et al. Imported Plasmodium vivax malaria: demographic and clinical features in nonimmune travelers. J. Travel. Med. 2004, 11:213-217.
76. Elmes N.J., Nasveld P.E., Kitchener S.J., Kocisko D.A., Edstein M.D. The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific. Trans. R. Soc. Trop. Med. Hyg. 2008, 102:1095-1101.
77. Feachem R.G., Phillips A.A., Targett G.A., Snow R.W. Call to action: priorities for malaria elimination. Lancet 2010, 376:1517-1521.
78. Fernandez-Becerra C., Pinazo M.J., Gonzalez A., Alonso P.L., del Portillo H.A., et al. Increased expression levels of the pvcrt-o and pvmdr1 genes in a patient with severe Plasmodium vivax malaria. Malar. J. 2009, 8:55.
79. Field J.W. Notes on the Chemotherapy of Malaria 1938, Bulletins from the Institute for Medical Research Federated Malay States Printing, Kuala Lumpur, 180 pp.
80. Freedman D.O., Weld L.H., Kozarsky P.E., Fisk T., Robins R., et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N. Engl. J. Med. 2006, 354:119-130.
81. Fryauff D.J., Baird J.K., Basri H., Sumawinata I., Purnomo, et al. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet 1995, 346:1190-1193.
82. Galappaththy G.N., Omari A.A., Tharyan P. Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database Syst. Rev. 2007, CD004389.
83. Gbotosho G.O., Happi C.T., Ganiyu A., Ogundahunsi O.A., Sowumni A., et al. Potential contribution of prescription practices to the emergence and spread of chloroquine resistance in south-west Nigeria: caution in the use of artemisinin combination therapy. Malar. J. 2009, 8:313.
84. Genton B., D'Acremont V., Rare L., Bae K., Reeder J.C., et al. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med. 2008, 5:6.
85. Gogtay N.J., Desai S., Kamtekar K.D., Kadam V.S., Dalvi S.S., et al. Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections. Ann. Trop. Med. Parasitol. 1999, 93:809-812.
86. Goller J.L., Jolley D., Ringwald P., Biggs B.A. Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy. Am. J. Trop. Med. Hyg. 2007, 76:203-207.
87. Grassi B., Feletti R. Parasites malariques ches oiseaux. Arch Ital de Biologie 1890, 13:297-300.
88. Greenwood D. Conflicts of interest: the genesis of synthetic antimalarial agents in peace and war. J. Antimicrob. Chemother. 1995, 36:857-872.
89. Guthmann J.P., Pittet A., Lesage A., Imwong M., Lindegardh N., et al. Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. Trop. Med. Int. Health 2008, 13:91-98.
90. Habib A.G., Singh K.S. Respiratory distress in nonimmune adults with imported malaria. Infection 2004, 32:356-359.
91. Hastings M.D., Porter K.M., Maguire J.D., Susanti I., Kania W., et al. Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. J. Infect. Dis. 2004, 189:744-750.
92. Hastings M.D., Maguire J.D., Bangs M.J., Zimmerman P.A., Reeder J.C., et al. Novel Plasmodium vivax dhfr alleles from the Indonesian Archipelago and Papua New Guinea: association with pyrimethamine resistance determined by a Saccharomyces cerevisiae expression system. Antimicrob. Agents Chemother. 2005, 49:733-740.
93. Hasugian A.R., Purba H.L., Kenangalem E., Wuwung R.M., Ebsworth E.P., et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin. Infect. Dis. 2007, 44:1067-1074.
94. Hasugian A.R., Tjitra E., Ratcliff A., Siswantoro H., Kenangalem E., et al. In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax. Antimicrob. Agents Chemother. 2009, 53:1094-1099.
95. Hill D.R., Baird J.K., Parise M.E., Lewis L.S., Ryan E.T., et al. Primaquine: Report from CDC expert meeting on malaria chemoprophylaxis I. Am. J. Trop. Med. Hyg. 2006, 75:402-415.
96. Hozhabri S., Luby S.P., Rahbar M.H., Akhtar S. Clinical diagnosis of Plasmodium falciparum among children with history of fever, Sindh, Pakistan. Int. J. Infect. Dis. 2002, 6:233-235.
97. Hung T.Y., Davis T.M., Ilett K.F., Karunajeewa H., Hewitt S., et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol. 2004, 57:253-262.
98. Imwong M., Snounou G., Pukrittayakamee S., Tanomsing N., Kim J.R., et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J. Infect. Dis. 2007, 195:927-933.
99. Imwong M., Pukrittayakamee S., Pongtavornpinyo W., Nakeesathit S., Nair S., et al. Gene amplification of the multidrug resistance 1 gene of Plasmodium vivax isolates from Thailand, Laos, and Myanmar. Antimicrob. Agents Chemother. 2008, 52:2657-2659.
100. Islam N., Qamruddin K. Unusual complications in benign tertian malaria. Trop. Geogr. Med. 1995, 47:141-143.
101. Jeffery G.M. Infectivity to mosquitoes of Plasmodium vivax following treatment with chloroquine and other antimalarials. Am. J. Trop. Med. Hyg. 1958, 7:207-211.
102. Jelinek T., Nothdurft H.D., Von Sonnenburg F., Loscher T. Long-term efficacy of primaquine in the treatment of vivax malaria in nonimmune travelers. Am. J. Trop. Med. Hyg. 1995, 52:322-324.
103. Jensen M., Mehlhorn H. 75 years of Resochin in the Fight Against Malaria 2009, Dusseldorf University Press, German, 102 pp.
104. Jones R., Jackson L.S., Di Lorenzo A., Marx R.L., Levy B.L., et al. Korean vivax malaria. III. Curative effect and toxicity of primaquine in doses from 10 to 30 mg. daily. Am. J. Trop. Med. Hyg. 1953, 2:977-982.
105. Jordan-Villegas A., Zapata J.C., Perdomo A.B., Quintero G.E., Solarte Y., et al. Aotus lemurinus griseimembra monkeys: a suitable model for Plasmodium vivax sporozoite infection. Am. J. Trop. Med. Hyg. 2005, 73:10-15.
106. Karunajeewa H., Lim C., Hung T.Y., Ilett K.F., Denis M.B., et al. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Br. J. Clin. Pharmacol. 2004, 57:93-99.
107. Karunajeewa H.A., Ilett K.F., Mueller I., Siba P., Law I., et al. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob. Agents Chemother. 2008, 52:237-243.
108. Karunajeewa H.A., Mueller I., Senn M., Lin E., Law I., et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N. Engl. J. Med. 2008, 359:2545-2557.
109. Ketema T., Getahun K., Bacha K. Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Halaba district, South Ethiopia. Parasit. Vectors 2011, 4:46.
110. Khantikul N., Butraporn P., Kim H.S., Leemingsawat S., Tempongko M.A., et al. Adherence to antimalarial drug therapy among vivax malaria patients in northern Thailand. J. Health Popul. Nutr. 2009, 27:4-13.
111. TM G6PD deficiency screening test, a point-of-care diagnostic for primaquine theraphy screening. PLoS ONE 2011, 6:12.
112. Kim Y.K., Kim C., Park I., Kim H.Y., Choi J.Y., et al. Therapeutic efficacy of chloroquine in Plasmodium vivax and the pvmdr1 polymorphisms in the Republic of Korea under mass chemoprophylaxis. Am. J. Trop. Med. Hyg. 2011, 84:532-534.
113. Kimura M., Miyake H., Kim H.S., Tanabe M., Arai M., et al. Species-specific PCR detection of malaria parasites by microtiter plate hybridization: clinical study with malaria patients. J. Clin. Microbiol. 1995, 33:2342-2346.
114. Kochar D.K., Saxena V., Singh N., Kochar S.K., Kumar S.V., et al. Plasmodium vivax malaria. Emerg. Infect. Dis. 2005, 11:132-134.
115. Koepfli C., Mueller I., Marfurt J., Goroti M., Sie A., et al. Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. J. Infect. Dis. 2009, 199:1074-1080.
116. Kolaczinski K., Durrani N., Rahim S., Rowland M. Sulfadoxine-pyrimethamine plus artesunate compared with chloroquine for the treatment of vivax malaria in areas co-endemic for Plasmodium falciparum and P. vivax: a randomised non-inferiority trial in eastern Afghanistan. Trans. R. Soc. Trop. Med. Hyg. 2007, 101:1081-1087.
117. Kotwal R.S., Wenzel R.B., Sterling R.A., Porter W.D., Jordan N.N., et al. An outbreak of malaria in US Army Rangers returning from Afghanistan. J. Am. Med. Assoc. 2005, 293:212-216.
118. Krotoski W.A., Garnham P.C., Cogswell F.B., Collins W.E., Bray R.S., et al. Observations on early and late post-sporozoite tissue stages in primate malaria. IV. Pre-erythrocytic schizonts and/or hypnozoites of Chesson and North Korean strains of Plasmodium vivax in the chimpanzee. Am. J. Trop. Med. Hyg. 1986, 35:263-274.
119. Krudsood S., Wilairatana P., Tangpukdee N., Chalermrut K., Srivilairit S., et al. Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmodium vivax malaria in Thailand. Korean J. Parasitol. 2006, 44:221-228.
120. Krudsood S., Tangpukdee N., Muangnoicharoen S., Thanachartwet V., Luplertlop N., et al. Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand. Korean J. Parasitol. 2007, 45:111-114.
121. Krudsood S., Tangpukdee N., Wilairatana P., Phophak N., Baird J.K., et al. High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 2008, 78:736-740.
122. Kumar S., Melzer M., Dodds P., Watson J., Ord R. P. vivax malaria complicated by shock and ARDS. Scand. J. Infect. Dis. 2007, 39:255-256.
123. Lacy M.D., Maguire J.D., Barcus M.J., Ling J., Bangs M.J., et al. Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. Clin. Infect. Dis. 2002, 35:e92-95.
124. Lawn S.D., Krishna S., Jarvis J.N., Joet T., Macallan D.C. Case reports: pernicious complications of benign tertian malaria. Trans. R. Soc. Trop. Med. Hyg. 2003, 97:551-553.
125. Lee S.W., Lee M., Lee D.D., Kim C., Kim Y.J., et al. Biological resistance of hydroxychloroquine for Plasmodium vivax malaria in the Republic of Korea. Am. J. Trop. Med. Hyg. 2009, 81:600-604.
126. Lek-Uthai U., Suwanarusk R., Ruengweerayut R., Skinner-Adams T.S., Nosten F., et al. Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum. Antimicrob. Agents Chemother. 2008, 52:2435-2441.
127. Leslie T., Rab M.A., Ahmadzai H., Durrani N., Fayaz M., et al. Compliance with 14-day primaquine therapy for radical cure of vivax malaria-a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Trans. R. Soc. Trop. Med. Hyg. 2004, 98:168-173.
128. Leslie T., Mayan I., Mohammed N., Erasmus P., Kolaczinski J., et al. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan. PLoS ONE 2008, 3:8.
129. LeYuan S., QingXia H. Observation on efficacy of pyronaridine phosphate and combined with dihydroartemisinin for treatment of malaria in Eritrea, Africa. Chin. J. Parasitic. Dis. Control 2001, 14:R382. 331.
130. Li X., Li C., Che L., Liu X., Li Z., et al. Observation on efficacy of artemether compound against vivax malaria. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 1999, 17:175-177.
131. Lomar A.V., Vidal J.E., Lomar F.P., Barbas C.V., de Matos G.J., et al. Acute respiratory distress syndrome due to vivax malaria: case report and literature review. Braz. J. Infect. Dis. 2005, 9:425-430.
132. Lu F., Gao Q., Zhou H., Cao J., Wang W., et al. Molecular test for vivax malaria with loop-mediated isothermal amplification method in central China. Parasitol. Res. 2011, 110:2439-2444.
133. Lysenko A.Y. Use of quinocide in treatment and prophylaxis of vivax malaria. Bull. World Health Organ. 1960, 22:641-662.
134. Maguire J.D., Krisin, Marwoto H., Richie T.L., Fryauff D.J., et al. Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia. Clin. Infect. Dis. 2006, 42:1067-1072.
135. Maguire J.D., Lederman E.R., Barcus M.J., O'Meara W.A., Jordon R.G., et al. Production and validation of durable, high quality standardized malaria microscopy slides for teaching, testing and quality assurance during an era of declining diagnostic proficiency. Malar. J. 2006, 5:92.
136. Maguire J.D., Fenton M.E., Susanti A.I., Walker J.B. Plasmodium vivax-associated acute respiratory distress syndrome after extended travel in Afghanistan. Travel Med. Infect. Dis. 2007, 5:301-305.
137. Manning L., Laman M., Law I., Bona C., Aipit S., et al. Features and prognosis of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed Plasmodium species in Papua New Guinean children. PLoS ONE 2011, 6:e29203.
138. Marfurt J., de Monbrison F., Brega S., Barbollat L., Muller I., et al. Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1. J. Infect. Dis. 2008, 198:409-417.
139. Marfurt J., Chalfein F., Prayoga P., Wabiser F., Kenangalem E., et al. Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax. Antimicrob. Agents Chemother. 2011, 55:961-966.
140. Marfurt J., Chalfein F., Prayoga P., Wabiser F., Kenangalem E., et al. Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax. Antimicrob. Agents Chemother. 2011, 55:4461-4464.
141. Marsh K. Research priorities for malaria elimination. Lancet 2010, 376:1626-1627.
142. Mayxay M., Thongpraseuth V., Khanthavong M., Lindegardh N., Barends M., et al. An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos). Trop. Med. Int. Health 2006, 11:1157-1165.
143. Mazier D., Landau I., Miltgen F., Druilhe P., Guguen-Guillouzo C., et al. In vitro infestation of human hepatocytes by sporozoites of Plasmodium vivax: schizogony and liberation of merozoites capable of infesting human erythrocytes. Ann. Parasitol. Hum. Comp. 1983, 58:405-406.
144. Mendis K., Sina B.J., Marchesini P., Carter R. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 2001, 64:97-106.
145. Millet P., Collins W.E., Herman L., Cochrane A.H. Plasmodium vivax: in vitro development of exoerythrocytic stages in squirrel monkey hepatocytes and inhibition by an anti-P. cynomolgi monoclonal antibody. Exp. Parasitol. 1989, 69:91-93.
146. Milne L.M., Kyi M.S., Chiodini P.L., Warhurst D.C. Accuracy of routine laboratory diagnosis of malaria in the United Kingdom. J. Clin. Pathol. 1994, 47:740-742.
147. Most H., Kane C.A., et al. Combined quinine-plasmochin treatment of vivax malaria; effect of relapse rate. Am. J. Med. Sci. 1946, 212:550-560.
148. Most H., London I.M., et al. Chloroquine for treatment of acute attacks of vivax malaria. J. Am. Med. Assoc. 1946, 131:963-967.
149. Munteis E., Mellibovsky L., Marquez M.A., Minguez S., Vazquez E., et al. Pulmonary involvement in a case of Plasmodium vivax malaria. Chest 1997, 111:834-835.
150. Mwangi T.W., Mohammed M., Dayo H., Snow R.W., Marsh K. Clinical algorithms for malaria diagnosis lack utility among people of different age groups. Trop. Med. Int. Health 2005, 10:530-536.
151. Myint H.Y., Tipmanee P., Nosten F., Day N.P., Pukrittayakamee S., et al. A systematic overview of published antimalarial drug trials. Trans. R. Soc. Trop. Med. Hyg. 2004, 98:73-81.
152. Nkhoma E.T., Poole C., Vannappagari V., Hall S.A., Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol. Dis. 2009, 42:267-278.
153. Nomura T., Carlton J.M., Baird J.K., del Portillo H.A., Fryauff D.J., et al. Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria. J. Infect. Dis. 2001, 183:1653-1661.
154. Nurleila S., Syafruddin D., Elyazar I.R.F., Baird J.K. Serious and fatal illness associated with falciparum and vivax malaria among patients admitted to hospital at West Sumba in Eastern Indonesia. Am. J. Trop. Med. Hyg. 2012, 87:41-49.
155. Obaldia N., Rossan R.N., Cooper R.D., Kyle D.E., Nuzum E.O., et al. WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys. Am. J. Trop. Med. Hyg. 1997, 56:508-510.
156. Office of the Surgeon General The drug treatment of malaria, suppressive and clinical. J. Am. Med. Assoc. 1943, 123:205-208. Circular Letter No. 153.
157. O'Meara W.P., Barcus M., Wongsrichanalai C., Muth S., Maguire J.D., et al. Reader technique as a source of variability in determining malaria parasite density by microscopy. Malar. J. 2006, 5:118.
158. Pannacciulli I., Tizianello A., Ajmar F., Salvidio E. The course of experimentally induced hemolytic anemia in a primaquine sensitive Caucasian. Blood 1965, 25:92-95.
159. Path Staying the course? Malaria Research and Development in a Time of Economic Uncertainty. Seattle PATH 2011, 87.
160. Perisse A.R., Strickland G.T. Usefulness of clinical algorithm as screening process to detected malaria in low-to-moderate transmission areas of scarce health related resources. Acta Trop. 2008, 107:224-229.
161. Perren A., Beretta F., Schubarth P. ARDS in Plasmodium vivax malaria. Schweiz. Med. Wochenschr. 1998, 128:1020-1023.
162. Phyo A.P., Lwin K.M., Price R.N., Ashley E.A., Russell B., et al. Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin. Infect. Dis. 2011, 53:977-984.
163. Poespoprodjo J.R., Fobia W., Kenangalem E., Lampah D.A., Warikar N., et al. Adverse pregnancy outcomes in an area where multidrug-resistant Plasmodium vivax and Plasmodium falciparum infections are endemic. J. Infect. Dis. 2008, 46:1374-1381.
164. Poespoprodjo J.R., Fobia W., Kenangalem E., Lampah D.A., Hasanuddin A., et al. Vivax malaria: a major cause of morbidity in early infancy. Clin. Infect. Dis. 2009, 48:1704-1712.
165. Poravuth Y., Socheat D., Rueangweerayut R., Uthaisin C., Pyae Phyo A., et al. Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS ONE 2011, 6:e14501.
166. Powell R.D., Brewer G.J. The effects of pyrimethamine, chloroquine, and primaquine against exoerythrocytic forms of a strain chloroquine-resistant Plasmodium falciparum from Thailand. Am. J. Trop. Med. Hyg. 1967, 16:693-698.
167. Price R.N., Douglas N.M. Maximizing the public health benefit of antimalarials. Lancet Infect. Dis. 2010, 10:654-655.
168. Price R., Nosten F., Simpson J.A., Luxemburger C., Phaipun L., et al. Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am. J. Trop. Med. Hyg. 1999, 60:1019-1023.
169. Price L., Planche T., Rayner C., Krishna S. Acute respiratory distress syndrome in Plasmodium vivax malaria: case report and review of the literature. Trans. R. Soc. Trop. Med. Hyg. 2007, 101:655-659.
170. Price R.N., Tjitra E., Guerra C.A., Yeung S., White N.J., et al. Vivax malaria: neglected and not benign. Am. J. Trop. Med. Hyg. 2007, 77:79-87.
171. Price R.N., Douglas N.M., Anstey N.M. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr. Opin. Infect. Dis. 2009, 22:430-435.
172. Price R.N., Marfurt J., Chalfein F., Kenangalem E., Piera K.A., et al. In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax. Antimicrob. Agents Chemother. 2010, 54:5146-5150.
173. Pukrittayakamee S., Chantra A., Vanijanonta S., White N.J. Pulmonary oedema in vivax malaria. Trans. R. Soc. Trop. Med. Hyg. 1998, 92:421-422.
174. Pukrittayakamee S., Chantra A., Simpson J.A., Vanijanonta S., Clemens R., et al. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob. Agents Chemother. 2000, 44:1680-1685.
175. Ratcliff A., Siswantoro H., Kenangalem E., Maristela R., Wuwung R.M., et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007, 369:757-765.
176. Ratcliff A., Siswantoro H., Kenangalem E., Wuwung M., Brockman A., et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans. R. Soc. Trop. Med. Hyg. 2007, 101:351-359.
177. Rieckmann K.H., Davis D.R., Hutton D.C. Plasmodium vivax resistance to chloroquine?. Lancet 1989, 2:1183-1184.
178. Rijken M.J., Boel M.E., Russell B., Imwong M., Leimanis M.L., et al. Chloroquine resistant vivax malaria in a pregnant woman on the western border of Thailand. Malar. J. 2011, 10:113.
179. Rocco F. Quinine: Malaria and the Quest for a Cure that Changed the World 2004, Harper Perennial, New York, 384 pp.
180. Rombo L., Ericsson O., Alván G., Lindström B., Gustafsson L.L., et al. Chloroquine and desethylchloroquine in plasma, serum, and whole blood: problems in assay and handling of samples. Ther. Drug. Monit. 1985, 7:211-215.
181. Rossan R.N., Young M.D., Baerg D.C. Chemotherapy of Plasmodium vivax in Saimiri and Aotus models. Am. J. Trop. Med. Hyg. 1975, 24:168-173.
182. Ruhe D.S., Cooper R.D., Coatney G.R., Josephson E.S. Studies in human malaria. XV. The therapeutic action of pamaquine (Plasmochin) against St. Elizabeth strain vivax malaria. Am. J. Hyg. 1949, 49:367-373.
183. Rungsihirunrat K., Sibley C.H., Mungthin M., Na-Bangchang K. Geographical distribution of amino acid mutations in Plasmodium vivax DHFR and DHPS from malaria endemic areas of Thailand. Am. J. Trop. Med. Hyg. 2008, 78:462-467.
184. Russel B., Chalfein G., Prasetyorini B., Kenangalem E., Piera K., et al. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob. Agents Chemother. 2008, 52:1040-1045.
185. Russell B.M., Udomsangpetch R., Rieckmann K.H., Kotecka B.M., Coleman R.E., et al. Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic. Antimicrob. Agents Chemother. 2003, 47:170-173.
186. Sa J.M., Nomura T., Neves J., Baird J.K., Wellems T.E., et al. Plasmodium vivax: allele variants of the mdr1 gene do not associate with chloroquine resistance among isolates from Brazil, Papua, and monkey-adapted strains. Exp. Parasitol. 2005, 109:256-259.
187. Sa J.M., Yamamoto M.M., Fernandez-Becerra C., de Azevedo M.F., Papakrivos J., et al. Expression and function of pvcrt-o, a Plasmodium vivax ortholog of pfcrt, in Plasmodium falciparum and Dictyostelium discoideum. Mol. Biochem. Parasitol. 2006, 150:219-228.
188. Saleri N., Gulletta M., Matteelli A., Caligaris S., Tomasoni L.R., et al. Acute respiratory distress syndrome in Plasmodium vivax malaria in traveler returning from Venezuela. J. Travel. Med. 2006, 13:112-113.
189. Sattabongkot J., Yimamnuaychoke N., Leelaudomlipi S., Rasameesoraj M., Jenwithisuk R., et al. Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocytic stages of the malaria parasites Plasmodium falciparum and P. vivax. Am. J. Trop. Med. Hyg. 2006, 74:708-715.
190. Schlitzer M. Malaria chemotherapeutics part I: history of antimalarial drug development, currently used therapeutics, and drugs in clinical development. Chem. Med. Chem. 2007, 2:944-986.
191. Schmidt L.H., Fradkin R., Vaughan D., Rasco J. Radical cure of infections with Plasmodium cynomolgi: a function of total 8-aminoquinoline dose. Am. J. Trop. Med. Hyg. 1977, 26:1116-1128.
192. Schmidt L.H., Fradkin R., Genther C., Rossan R.N., Squires W. Responses of sporozoite-induced and trophozoite-induced infections to standard antimalarials. Am. J. Trop. Med. Hyg. 1982, 31:646-665.
193. Schmidt L.H. Plasmodium falciparum and Plasmodium vivax infections in the owl monkey (Aotus trivirgatus). II. Responses to chloroquine, quinine, and pyrimethamine. Am. J. Trop. Med. Hyg. 1978, 27:703-717.
194. Schmidt L.H. Comparative efficacies of quinine and chloroquine as companions to primaquine in a curative drug regimen. Am. J. Trop. Med. Hyg. 1981, 30:20-25.
195. Schmidt L.H. Appraisals of compounds of diverse chemical classes for capacities to cure infections with sporozoites of Plasmodium cynomolgi. Am. J. Trop. Med. Hyg. 1983, 32:231-257.
196. Schmidt L.H. Enhancement of the curative activity of primaquine by concomitant administration of mirincamycin. Antimicrob. Agents Chemother. 1985, 27:151-157.
197. Shaikh S., Memon H., Shaikh A., Ahmed I., Iohano B., et al. Severe disease in children hospitalized with a diagnosis of Plasmodium vivax in south-eastern Pakistan. Malar. J. 2012, 11:144.
198. Shannon J.A. Chemotherapy in malaria. Bull. N. Y. Acad. Med. 1946, 22:345-357.
199. Sharrock W.W., Suwanarusk R., Lek-Uthai U., Edstein M.D., Kosaisavee V., et al. Plasmodium vivax trophozoites insensitive to chloroquine. Malar. J. 2008, 7:94.
200. Sinclair D., Gogtay N., Brand F., Olliaro P. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst. Rev. 2011, CD008492.
201. Sinton J.A., Bird W. Studies in malaria with special reference to treatment. IX. Plasmoquine in the treatment of malaria. Indian J. Med. Res. 1928, 16:159-177.
202. Sinton J.A., Smith S., Pottinger D. Studies in malaria with special reference to treatment. XII. Further researches into the treatment of chronic benign tertian malaria with plasmoquine and quinine. Indian J. Med. Res. 1930, 17:793-814.
203. Smithuis F., Kyaw M.K., Phe O., Aye K.Z., Htet L., et al. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet 2006, 367:2075-2085.
204. Smithuis F., Kyaw M.K., Phe O., Win T., Aung P.P., et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect. Dis. 2010, 10:673-681.
205. Srivastava H.C., Yadav R.S., Joshi H., Valecha N., Mallick P.K., et al. Therapeutic responses of Plasmodium vivax and P. falciparum to chloroquine, in an area of western India where P. vivax predominates. Ann. Trop. Med. Parasitol. 2008, 102:471-480.
206. Sullivan J.S., Morris C.L., Richardson B.B., Galland G.G., Jennings V.M., et al. Adaptation of the AMRU-1 strain of Plasmodium vivax to Aotus and Saimiri monkeys and to four species of anopheline mosquitoes. J. Parasitol. 1999, 85:672-677.
207. Sullivan J.S., Strobert E., Yang C., Morris C.L., Galland G.G., et al. Adaptation of a strain of Plasmodium vivax from India to New World monkeys, chimpanzees, and anopheline mosquitoes. J. Parasitol. 2001, 87:1398-1403.
208. Sumawinata I.W., Bernadeta, Leksana B., Sutamihardja A., Purnomo, et al. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am. J. Trop. Med. Hyg. 2003, 68:416-420.
209. Sutanto I., Suprijanto S., Nurhayati, Manoempil P., Baird J.K. Resistance to chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in eastern Indonesia. Am. J. Trop. Med. Hyg. 2009, 81:338-342.
210. Sutanto I., Endawati D., Ling L.H., Laihad F., Setiabudy R., et al. Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia. Malar. J. 2010, 9(52):52.
211. Sutanto, I., Efficacy of primaquine when combined with quinine or dihydroartemisinin-piperaquine against relapse, in preparation.
212. Suwanarusk R., Russell B., Chavchich M., Chalfein F., Kenangalem E., et al. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS ONE 2007, 2:e1089.
213. Suwanarusk R., Chavchich M., Russell B., Jaidee A., Chalfein F., et al. Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax. J. Infect. Dis. 2008, 198:1558-1564.
214. Swartz E., Parise M., Kozarsky P., Cetron M. Delayed onset malaria - implications for chemoprophylaxis in travelers. N. Engl. J. Med. 2003, 349:1510-1516.
215. Tanios M.A., Kogelman L., McGovern B., Hassoun P.M. Acute respiratory distress syndrome complicating Plasmodium vivax malaria. Crit. Care. Med. 2001, 29:665-667.
216. Tao Z.Y., Zhou H.Y., Xia H., Xu S., Zhu H.W., et al. Adaptation of a visualized loop-mediated isothermal amplification technique for field detection of Plasmodium vivax infection. Parasit. Vectors 2011, 4:115.
217. Tasanor O., Ruengweerayut R., Sirichaisinthop J., Congpuong K., Wernsdorfer W.H., et al. Clinical-parasitological response and in-vitro sensitivity of Plasmodium vivax to chloroquine and quinine on the western border of Thailand. Trans. R. Soc. Trop. Med. Hyg. 2006, 100:410-418.
218. Taylor N. Chinchona in Java: The Story of Quinine 1945, Greenberg, New York, pp. 87.
219. Tjitra E., Baker J., Suprianto S., Cheng Q., Anstey N.M. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob. Agents Chemother. 2002, 46:3947-3953.
220. Tjitra E., Anstey N.M., Sugiarto P., Warikar W., Kenangalem E., et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 2008, 5:6.
221. Torres J.R., Perez H., Postigo M.M., Silva J.R. Acute non-cardiogenic lung injury in benign tertian malaria. Lancet 1997, 350:31-32.
222. Udomsangpetch R., Somsri S., Panichakul T., Chotivanich K., Sirichaisinthop J., et al. Short-term in vitro culture of field isolates of Plasmodium vivax using umbilical cord blood. Parasitol. Int. 2007, 56:65-69.
223. Weiss W.R., Oloo A.J., Johnson A., Koech D., Hoffman S.L. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J. Infect. Dis. 1995, 171:1569-1575.
224. Wells T.N., Burrows J.N., Baird J.K. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 2010, 26:145-151.
225. Whitby M., Wood G., Veenendaal J.R., Rieckmann K. Chloroquine-resistant Plasmodium vivax. Lancet 1989, 2:1395.
226. White N.J., Olliaro P.L. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol. Today 1996, 12:399-401.
227. White N.J., Stepniewska K., Barnes K., Price R.N., Simpson J. Simplified antimalarial therapeutic monitoring: using the day-7 drug level?. Trends Parasitol. 2008, 24:159-163.
228. White N. Antimalarial drug resistance and combination chemotherapy. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1999, 354:739-749.
229. White N.J. How antimalarial drug resistance affects post-treatment prophylaxis. Malar. J. 2008, 7:9.
230. White N.J. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar. J. 2011, 10:297.
231. Whitty C.J., Chandler C., Ansah E., Leslie T., Staedke S.G. Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. Malar. J. 2008, 7(Suppl. 1):S7.
232. WHO Global Malaria Programme Malaria Rapid Diagnostic Test performance 2009, Summary results of WHO product testing of malaria RDTs: Round 1 and 2 (2008-2009). Available:. http://www2wprowhoint/NR/rdonlyres/E4823BBF-69FC-45DE-B924-1A9FCDD7406C/0/RoundIII_SummaryFINALpdf.
233. Wilson M.E., Weld L.H., Boggild A., Keystone J.S., Kain K.C., et al. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis 2007, 44:1560-1568.
234. Wiselogle F.Y. A Survey of Antimalarial Drug, 1941-1945 1946, Michigan, Ann Arbor.
235. World Health Organization Malaria microscopy quality assurance manual 2009, Version 1. 125 p.
236. World Health Organization World Malaria Report 2009 2009, 1-66.
237. World Health Organization Guidelines for the Treatment of Malaria 2010, WC 770: 191 p. Second ed.
238. World Health Organization WHO Global Malaria Programme: Information Note on Recommended Selection Criteria for Procurement of Malaria Rapid Diagnostic Tests (RDTs) 2012, WHO 12 April 2012. Available at:. http://wwwwhoint/malaria/diagnosis_treatment/diagnosis/RDT_selection_criteriapdf.
239. Yadav R.S., Ghosh S.K. Radical curative efficacy of five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India. J. Parasitol. 2002, 88:1042-1044.
240. Yohannes A.M., Teklehaimanot A., Bergqvist Y., Ringwald P. Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia. Am. J. Trop. Med. Hyg. 2011, 84:137-140.
241. Zakeri S., Motmaen S.R., Afsharpad M., Djadid N.D. Molecular characterization of antifolates resistance-associated genes, (dhfr and dhps) in Plasmodium vivax isolates from the Middle East. Malar. J. 2009, 8:20.
242. Ziai M., Amirhakimi G.H., Reinhold J.G., Tabatabee M., Gettner M.E., et al. Malaria prophylaxis and treatment in G-6-PD deficiency. An observation on the toxicity of primaquine and chloroquine. Clin. Pediatr. 1967, 6:242-243.